Navigation Links
LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
Date:2/1/2010

rious adverse events reported. The trials were initiated and run by Peplin, Inc., acquired by LEO Pharma in September 2009.  

Results from REGION I and Ib will be presented at an upcoming meeting of the American Academy of Dermatology.

LEO Pharma expects to file for regulatory approval of the treatment in the U.S. and Europe in 2011.

About Actinic Keratosis

Actinic keratosis (AK) is a common pre-cancerous skin condition caused by sun exposure, which can develop into skin cancers if left untreated. The number of AK patients is both large and rapidly growing, and AK is a serious health problem.

About LEO Pharma

Founded more than 100 years ago, LEO Pharma is an independent, research-based specialty pharmaceutical company committed to the discovery and development of novel drugs for patients within the areas of Dermatology and Critical Care Medicine. Wholly owned by The LEO Foundation, the company is headquartered in Ballerup, Denmark, outside of Copenhagen, and is represented in more than 90 countries worldwide.  Employees number more than 3,000, with 550 scientists and specialists working to develop new chemical entities.

With a strong portfolio of approved products and a robust pipeline of treatments in development for conditions including psoriasis, eczema and actinic (solar) keratosis, LEO Pharma is one of the leading dermatology companies in the U.S. and the world.  

For more information about LEO Pharma, visit www.leopharma.com.

SOURCE LEO Pharma

RELATED LINKS'/>"/>

SOURCE LEO Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
5. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
6. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
7. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
8. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
11. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), a ... approved CytoSorb® cytokine adsorber to treat critically-ill patients ... of Light Award at last night,s New Jersey ... Dr. Phillip Chan , Chief Executive Officer ... be recognized by the New Jersey Tech Council ...
(Date:11/22/2014)... de 2014  BioClinica®, Inc., un proveedor líder ... eClinical, ha indicado un aumento de la demanda ... seguimiento basado en el riesgo en los ensayos ... seguimiento basado en el riesgo más allá de ... o cambio de los métodos de seguimiento. Se ...
(Date:11/22/2014)... , Nov. 21, 2014   Long Beach dentist ... are often called the gold standard in tooth replacement because ... a stable, long-lasting way to restore and preserve smiles and ... to replace a missing tooth or as a part of ... the look and feel of a smile. The ...
Breaking Medicine Technology:CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2
... AccuVein LLC today announced it had signed an exclusive distribution ... vein finder in India . With this new agreement ... , , ... blood draw , IV infusion and blood donation by projecting ...
... May 18 Teva Women ,s Health, Inc. ... or low dose of ENJUVIA® (synthetic conjugated estrogens, B) tablets ... at night by hot flashes compared to patients treated with ... Clinical Meeting of the American College of Obstetricians and Gynecologists ...
Cached Medicine Technology:AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 2AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 2New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 3New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 4New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 5New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 6New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women 7
(Date:11/22/2014)... is an important company in the dress industry. The ... online market share by a series of promotions. Recently, it ... a bridesmaid dress promotion for the new year 2015. The ... dresses from this company are not only of high quality ... good at manufacturing wedding dresses. Customers prefer to choose the ...
(Date:11/22/2014)... to provide better services, LunaDress has updated its website with ... that a suitable cocktail party dress is crucial for every ... dresses supplier’s high quality items are offered at attracting prices, ... industry, LunaDress understands that it is not easy to provide ... the professional level and innovation ability. The growth of sales ...
(Date:11/22/2014)... Dallas, TX (PRWEB) November 22, 2014 ... Society (ICS) as the complaint that the individual ... times for voiding. The report “Nocturia – Pipeline ... therapeutic development for Nocturia, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
(Date:11/22/2014)... "My friend went in for a mammogram and ... an inventor from Cambria Heights, N.Y. "To add insult ... time because the first results were inaccurate. Her misfortune ... MAMO EASY to offer a more comfortable way to ... from the pain normally involved with this procedure. The ...
(Date:11/22/2014)... November 22, 2014 A petition seeking ... http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and fibroid removal ... the end of October, Bernstein Liebhard LLP reports. ... as of November 21st, 2014. That represents an increase ... had signed on to the campaign.* , The campaign ...
Breaking Medicine News(10 mins):Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
... (HealthDay News) -- Children who are allergic to penicillin ... additional drug allergies, new research suggests. Pediatric patients ... authors noted. Prior research in adults has suggested that ... allergies to other medications. But in the new ...
... one Michigan State University professor will explore why in old ... whites. Prior research also shows of those 71 years ... mild cognitive impairment, or various types of mental processing problems, ... first to produce statistics about life expectancy with and without ...
... new study conducted by Boston University School of Medicine (BUSM) ... believe that chewing the plant khat is harmful to one,s ... The study, which is published online in the journal ... 2013 students Paul Yi, John Kim and Khalil Hussein. Richard ...
... warned that, in addition to causing obesity, eating too ... risk for colon cancer. Now, researchers at Temple University ... The findings, "Epigenetic Differences in Normal Colon Mucosa of ... in the March issue of the American Association for ...
... HIV-positive patient, one of her first questions is whether he ... response is about dead relatives or friends. "We talk about ... experience will be very different," said the infectious-disease specialist at ... "Yes it,s the same virus and could have the same ...
... - Researchers from Boston University School of Medicine (BUSM) ... with breast pain who receive imaging (mammograms, MRIs or ... diagnostic testing, but do not gain benefit from these ... Journal of General Internal Medicine. Breast pain ...
Cached Medicine News:Health News:Kids' Penicillin Allergy May Not Signal Other Drug Reactions 2Health News:New research will shed light on racial gap in dementia 2Health News:BUSM student-published study focuses on khat chewing in Yemeni culture 2Health News:Study shows how high-fat diets increase colon cancer risk 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 3Health News:Research finds little benefit of breast imaging tests for women with breast pain 2
For the quantitative determination of Inorganic Phosphorus in serum. Linearity: 12.0 mg/dl....
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
For the kinetic quantitative determination of g-Glutamyl Transferase in serum for manual and/or automated procedures....
Intended for the quantitative determination of alphaamylase activity in serum. Single vial, dry powder reagent. Reaction: Kinetic. Wavelength: 405 nm. Linearity: 2000 U/L at 37C....
Medicine Products: